Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas
- 1 January 2003
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 98 (1), 145-153
- https://doi.org/10.3171/jns.2003.98.1.0145
Abstract
OBJECT: Craniopharyngiomas are histopathologically defined as benign tumors that can behave very aggressively at the clinical level. They can originate from different types of embryonal epithelial tissue in which correct spatiotemporal regulation has been disrupted at the effector production level. The goal of this study was to determine the efficacy of using selected biological markers to distinguish between recurring and nonrecurring craniopharyngiomas. METHODS: The authors used computer-assisted microscopy to determine quantitatively the immunohistochemical levels of expression of selected markers, including retinoic acid receptors (RARs), as response elements to retinoic acid in a series of 51 adamantinomatous craniopharyngiomas. These tumors may also originate as the result of physiological defects in the apoptosis-mediated elimination of embryological remnants of epithelial tissue. Galectin-3, p53, and the macrophage migration inhibiting factor (MIF) are known to play crucial roles in these processes. The authors quantitatively determined the levels of expression of these substances in this series of 51 craniopharyngiomas. The data show that all craniopharyngiomas were immunoreactive for RARalpha, whereas their immunoreactivity for RARbeta and RARgamma varied dramatically from one case to another. Craniopharyngiomas with low levels of RARbeta and high levels of RARgamma are more likely to recur than those with higher levels of RARbeta and lower levels of RARgamma. Rapidly recurring craniopharyngiomas also show significantly lower levels of expression of galectin-3 and MIF than nonrecurring or slowly recurring cases. Few tumors exhibited p53 immunopositivity. CONCLUSIONS: The data indicate that even in the so-called adamantinomatous group of craniopharyngiomas, several subgroups with different clinical behavior patterns can be identified on the basis of differentiation markers relating mainly to the presence or absence of RARbeta and RARgamma.Journal ArticleResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publisheKeywords
This publication has 41 references indexed in Scilit:
- Evidence for a role of macrophage migration inhibitory factor in psoriatic skin diseaseBritish Journal of Dermatology, 1999
- Ultraviolet B Radiation Upregulates the Production of Macrophage Migration Inhibitory Factor (MIF) in Human Epidermal KeratinocytesJournal of Investigative Dermatology, 1999
- Retinoic Acid Receptor-γ in Human Epidermis Preferentially Traps All-Trans Retinoic Acid as its Ligand Rather Than 9-cis Retinoic AcidJournal of Investigative Dermatology, 1998
- Macrophage Migration Inhibitory Factor Is an Essential Immunoregulatory Cytokine in Atopic DermatitisBiochemical and Biophysical Research Communications, 1997
- Incomplete Differentiation of Fetal Keratinocytes in the Skin Equivalent Leads to the Default Pathway of ApoptosisExperimental Cell Research, 1997
- Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localizationFEBS Letters, 1996
- Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: Relationship to keratinocyte proliferation, differentiation, and programmed cell deathThe Laryngoscope, 1995
- Papillary craniopharyngioma: a clinicopathological study of 48 casesJournal of Neurosurgery, 1995
- Immunohistochemical expression of human chorionic gonadotropin and P-glycoprotein in human pituitary glands and craniopharyngiomasJournal of Neurosurgery, 1994
- Correlation of clinical and pathological features in surgically treated craniopharyngiomasJournal of Neurosurgery, 1990